Late Breaking: Zolbetuximab + chemo as new potential standard treatment for patients with unresectable, metastatic gastric,  or gastro-esophageal junction adenocarcinoma 

Preliminary results from the phase 3 SPOTLIGHT study indicates Zolbetuximab combined with first-line chemotherapy (mFOLFOX6) to have significantly longer progression-free survival (PFS) and overall survival (OS) in patients with claudin 18.2 (CLDN18.2)-positive/HER2-, unresectable, or metastatic gastric or gastro-esophageal junction adenocarcinoma.